Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Hims & Hers stock is on the upswing after the company secured a weight-loss drug partnership. Hims & Hers is acquiring its ...

Hims & Hers (NYSE: HIMS) stock, a prominent player in the booming telehealth sector, has undeniably captured significant investor attention recently. Perhaps you, like many others, have been caught up ...

Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

Telehealth platform Hims & Hers will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on ...

Hims & Hers Health has seen massive success, aided by the growing use of GLP-1 drugs. Click here to find out why I downgrade ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

This fast growth has created some high expectations for Hims & Hers stock. It now has a price-to-earnings ratio (P/E) of 79, ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...